Characteristics | n (%) |
---|---|
Age, years | |
 Median | 56 |
 Range | 25–90 |
FIGO stage | |
 IB1–IIA2 | 77 (7.7) |
 IIB | 456 (45.5) |
 IIIA | 62 (6.2) |
 IIIB | 393 (39.2) |
 IVA | 14 (1.4) |
Histology | |
 Squamous carcinoma | 970 (96.8) |
 Adenocarcinoma | 29 (2.9) |
 Adenosquamous carcinoma | 3 (0.3) |
Concurrent chemotherapy | |
 Yes | 708 (70.7) |
 No | 294 (29.3 |
Consolidate chemotherapy | |
 Yes | 368 (36.7) |
 No | 634 (63.3) |
Three-dimensional brachytherapy | |
 Yes | 32 (3.2) |
 No | |
Patients with LNs | 970 (96.8) |
 Yes | 580 (57.9) |
 No | 422 (42.1) |
Patients with LNs in different locations | |
 Pelvic only | 491 (49) |
 Para-aortic ± pelvic | 89 (8.9) |
Number of LNs | 1310 |
Number of LNs per patient | |
 Median | 2 |
 Range | 1–16 |
Short diameter of LNs | |
 Range, cm | 0.4–4.8 |
  < 1 cm | 878 (67) |
 1–2 cm | 374 (28.5) |
  ≥ 2 cm | 58 (4.4) |
 Range of LNs ≥ 2 cm, cm | 2–4.8 |
 Median of LNs ≥ 2 cm, cm | 2.25 |